日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Differential Pharmacodynamic Effects on Psoriatic Biomarkers by Guselkumab Versus Secukinumab Correlate with Long-Term Efficacy: An ECLIPSE Substudy

古塞库单抗与司库奇尤单抗对银屑病生物标志物的差异性药效学影响与长期疗效相关:一项 ECLIPSE 子研究

Blauvelt, Andrew; Chen, Yanqing; Branigan, Patrick J; Liu, Xuejun; DePrimo, Samuel; Keyes, Brice E; Leung, Monica; Fakharzadeh, Steven; Yang, Ya-Wen; Muñoz-Elías, Ernesto J; Krueger, James G; Langley, Richard G

Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy

古塞库单抗比阿达木单抗更能降低银屑病患者的疾病和机制相关生物标志物:VOYAGE 1 子研究

Andrew Blauvelt, Richard G Langley, Patrick J Branigan, Xuejun Liu, Yanqing Chen, Samuel DePrimo, Keying Ma, Brittney Scott, Kim Campbell, Ernesto J Muñoz-Elías, Kim A Papp

Broad proteomic screen reveals shared serum proteomic signature in patients with psoriatic arthritis and psoriasis without arthritis

广泛的蛋白质组学筛选揭示了银屑病关节炎患者和非关节炎银屑病患者共同的血清蛋白质组学特征

Leijten, Emmerik; Tao, Weiyang; Pouw, Juliette; van Kempen, Tessa; Olde Nordkamp, Michel; Balak, Deepak; Tekstra, J; Muñoz-Elías, Ernesto; DePrimo, Samuel; Drylewicz, Julia; Pandit, Aridaman; Boes, Marianne; Radstake, Timothy

Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534

RORγt抑制剂JNJ-61803534的临床前和临床表征

Xiaohua Xue, Aimee De Leon-Tabaldo, Rosa Luna-Roman, Glenda Castro, Michael Albers, Freddy Schoetens, Samuel DePrimo, Damayanthi Devineni, Thomas Wilde, Steve Goldberg, Olaf Kinzel, Thomas Hoffmann, Anne M Fourie, Robin L Thurmond

Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours.

循环细胞因子和单核细胞亚群作为舒尼替尼治疗晚期神经内分泌肿瘤患者的疗效和生物活性的生物标志物

Zurita A J, Khajavi M, Wu H-K, Tye L, Huang X, Kulke M H, Lenz H-J, Meropol N J, Carley W, DePrimo S E, Lin E, Wang X, Harmon C S, Heymach J V

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.

循环蛋白作为治疗初治转移性肾细胞癌患者舒尼替尼和干扰素-α疗效的潜在生物标志物

Harmon Charles S, DePrimo Samuel E, Figlin Robert A, Hudes Gary R, Hutson Thomas E, Michaelson M Dror, Négrier Sylvie, Kim Sindy T, Huang Xin, Williams J Andrew, Eisen Tim, Motzer Robert J

Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib

可溶性KIT与接受舒尼替尼治疗的转移性乳腺癌患者的临床结果相关

Keyvanjah, Kiana; DePrimo, Samuel E; Harmon, Charles S; Huang, Xin; Kern, Kenneth A; Carley, William

Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib

机制相关循环蛋白作为接受舒尼替尼治疗的不可切除肝细胞癌患者临床结果的生物标志物

Charles S Harmon, Samuel E DePrimo, Eric Raymond, Ann-Lii Cheng, Eveline Boucher, Jean-Yves Douillard, Ho Y Lim, Jun S Kim, Maria José Lechuga, Silvana Lanzalone, Xun Lin, Sandrine Faivre

Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure

可溶性 KIT 的循环水平可作为伊马替尼治疗失败后接受舒尼替尼治疗的胃肠道间质瘤患者临床结果的生物标志物

Samuel E Deprimo, Xin Huang, Martin E Blackstein, Christopher R Garrett, Charles S Harmon, Patrick Schöffski, Manisha H Shah, Jaap Verweij, Charles M Baum, George D Demetri

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma

舒尼替尼对贝伐单抗耐药转移性肾细胞癌患者的抗肿瘤活性和生物标志物分析

Brian I Rini, M Dror Michaelson, Jonathan E Rosenberg, Ronald M Bukowski, Jeffrey A Sosman, Walter M Stadler, Thomas E Hutson, Kim Margolin, Charles S Harmon, Samuel E DePrimo, Sindy T Kim, Isan Chen, Daniel J George